Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Sells $356,160.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the sale, the director directly owned 11,486 shares of the company's stock, valued at $459,440. The trade was a 43.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock traded up $1.31 on Wednesday, reaching $41.07. 26,967 shares of the company traded hands, compared to its average volume of 362,258. Monopar Therapeutics Inc. has a 52 week low of $1.72 and a 52 week high of $54.30. The company has a 50 day moving average of $35.63 and a 200 day moving average of $35.88. The firm has a market capitalization of $251.35 million, a PE ratio of -11.80 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. As a group, analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics in a research report on Monday, July 7th. They issued an "overweight" rating and a $74.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Chardan Capital assumed coverage on shares of Monopar Therapeutics in a research report on Monday, June 23rd. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $60.00.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently modified their holdings of MNPR. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $23,435,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $13,182,000. RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $11,247,000. Point72 Asset Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $2,861,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.